J&J forecasts strong 2023 profit on strength in pharma unit

J&J forecasts strong 2023 profit on strength in pharma unit

(Reuters) -Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates as it bets on stronger demand for its pharmaceuticals products and a recovery in its medical devices business.

J&J said it was expecting to earn between $10.45 and $10.65 per share on an adjusted basis for 2023, above analysts estimates of $10.35 per share profit at midpoint.

The healthcare conglomerate also beat estimates for fourth-quarter profit on Tuesday as increased sales of pharmaceutical products helped it weather a hit from a stronger dollar

Excluding items, J&J earned $2.35 per share, above analysts average estimates of $2.23 per share, according to IBES data from Refinitiv.

(Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Anil DSilva)

3 Semiconductor Stocks Racing Higher in 2023ETH Bulls to Retarget $1,700 on US Stats and Hard Fork NewsNatural Gas Showing Early Signs It Wants to Go HigherS&P 500s Rally to $4300+ Is UnderwayEurozone Private Sector Expands for the First Time Since JuneGold Price Forecast XAU/USD – Firming on Easier Treasury Yields Ahead of Key US PMI DataLoadingLoadingLoading